Eli Lilly & Insilico: How Generative AI can Transform Pharma

The pharmaceutical sector is shifting towards an automated, data-driven approach to research and development through integrating generative AI with conventional drug discovery methods.

Biotechnology firm, Insilico Medicine, which specialises in generative AI and automation technologies, has entered into a partnership with pharmaceutical manufacturer Eli Lilly. The collaboration aims to expedite the identification and development of new therapeutic candidates spanning several treatment areas.

Pharma.AI represents an integrated suite engineered to streamline the complete drug development workflow, from selecting biological targets through to forecasting clinical efficacy. The platform seeks to substitute lengthy experimental testing with rapid AI-driven simulations.

The system employs several distinct components working in concert. The PandaOmics platform examines biological datasets to identify the particular malfunctioning protein or gene, the target, responsible for driving disease pathology.

Following target identification, Insilico's Chemistry42 platform generates and constructs novel molecular structures capable of binding to and modulating that specific target.

Concurrently, the inClinco component evaluates historical clinical trial data to forecast the likelihood of a candidate drug achieving success in human studies, potentially helping teams circumvent costly development failures.

Commercial terms of the agreement

The partnership carries a potential value reaching US$2.75bn and provides Lilly with exclusive global rights for development, manufacture and commercialisation of novel oral therapeutics currently in preclinical stages.

Under the financial structure, Insilico receives US$115m as an initial payment, with additional funds tied to development, regulatory and commercial milestones.

"From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery," says Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.

"By developing frontier AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time."

Alex adds that working with Lilly, the company aims to deliver transformative therapies that treat diseases with high unmet need.

"This collaboration is a testament to the power of AI in tackling the most complex challenges in human health," he explains.

Combining complementary capabilities

The two organisations will undertake joint work across multiple research and development initiatives centred on targets identified by Lilly. This approach merges Insilico's Pharma.AI platforms with Lilly's development infrastructure and therapeutic area knowledge.

Andrew Adams, Group Vice President of Molecule Discovery at Lilly, notes that "Insilico's AI-enabled discovery capabilities represent a powerful compliment to Lilly's deep expertise in clinical development across multiple therapeutic areas."

The collaboration could signal a broader industry trend towards computational approaches in pharmaceutical development. By leveraging AI systems throughout drug discovery, the partners suggest it may be possible to reduce development timelines and improve success rates in bringing new medicines to market.

Implications for drug development

The partnership demonstrates how established pharmaceutical manufacturers are incorporating AI-focused biotechnology firms into their research operations through strategic partnerships rather than developing capabilities entirely in-house.

For Insilico, the collaboration provides validation of its AI-driven approach, with the substantial financial commitment suggesting confidence in these technologies to contribute meaningfully to therapeutic development.

The arrangement reflects the pharmaceutical industry's growing emphasis on computational tools and artificial intelligence as core components of research and development, representing an attempt to address unmet medical needs through advanced AI systems.